Related Experiment Video
Updated: Jan 23, 2026

Author Spotlight: Recent Advancements in Reoperative Foregut Surgery
Published on: September 22, 2023
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection
Laura M Enomoto1, Perry Shen1, Edward A Levine1
1Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston Salem, NC 27157, USA.
Abstract:
Malignant peritoneal mesothelioma (MPM) is a rare, aggressive malignancy that typically presents with vague symptoms, ascites, and/or diffuse peritoneal studding. Despite findings of advanced disease within the peritoneal cavity, spread beyond the abdomen is uncommon. Although advances in systemic chemotherapy have been made, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remain the mainstay of treatment. Median overall survival of approximately 50 months with CRS/HIPEC has been demonstrated, with age, gender, histologic subtype, peritoneal carcinomatosis index, comorbidities, nodal and extra-abdominal metastases, and completeness of cytoreduction all playing a role in prognosis. In patients with refractory malignant ascites and unresectable disease, complete resolution of ascites and improvement in quality of life have been demonstrated with palliative HIPEC. In appropriately selected patients, CRS/HIPEC plays a critical role in the treatment and palliation of MPM.
Insights
Malignant peritoneal mesothelioma (MPM) is a rare cancer. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers significant survival benefits and palliation for MPM patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer.
- MPM often presents with vague symptoms and ascites, with advanced disease confined to the peritoneum.
Purpose of the Study:
- To review the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment and palliation of MPM.
- To discuss prognostic factors influencing survival in MPM patients treated with CRS/HIPEC.
Main Methods:
- Review of current literature on MPM treatment, focusing on CRS/HIPEC.
- Analysis of prognostic factors affecting outcomes in MPM.
Main Results:
- CRS/HIPEC is the established treatment for MPM, demonstrating a median overall survival of approximately 50 months.
- Prognostic factors include age, gender, histology, peritoneal carcinomatosis index, comorbidities, nodal status, and completeness of cytoreduction.
- Palliative HIPEC can resolve refractory malignant ascites and improve quality of life in unresectable cases.
Conclusions:
- CRS/HIPEC is critical for both curative treatment and palliation of MPM.
- Patient selection and achieving complete cytoreduction are key to optimal outcomes in MPM management.
More Related Videos
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Special considerations while measuring pulse
Special considerations while measuring blood pressure
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
Special considerations while measuring oxygen saturation
Ensuring accuracy in vital sign recordings while prioritizing patient comfort and minimizing anxiety is...
Special Staining Techniques
Design Consideration
The factor of safety is another key...
Introduction to Special Senses